| Cat. No. |
Product Name |
Information |
| PC-60010 |
Allitinib
|
Allitinib (AST-1306, ALS1306)) is a novel potent, selective irreversible EGFR and HER2 inhibitor with IC50 of 0.5 and 3 nM in cell-free assays. |
| PC-45690 |
Olmutinib
|
Olmutinib (HM61713, BI-1482694) is a pontent and T790M-specific third-generation EGFR inhibitor for treatment of NSCLC. |
| PC-45722 |
Naquotinib mesylate
EGFR inhibitor
|
Naquotinib (ASP-8273) is a potent, irreversible, mutant-selective inhibitor of EGFR (IC50=8-33 nM for (L858R, exon 19 deletion, L858R/T790M, and del19/T790M)). |
| PC-45689 |
Naquotinib
EGFR inhibitor
|
Naquotinib (ASP-8273) is a potent, irreversible, mutant-selective inhibitor of EGFR (IC50=8-33 nM for (L858R, exon 19 deletion, L858R/T790M, and del19/T790M)). |
| PC-45681 |
Anlotinib
Multikinase inhibitor
|
Anlotinib (AL-3818) is a novel multi-target tyrosine kinase that primarily inhibit VEGFR2/3, FGFR1-4, PDGFR α/β, c-Kit, and Ret. |
| PC-42500 |
Afatinib dimaleate
EGFR inhibitor
|
Afatinib (BIBW 2992) dimaleate is an irreversible, dual EGFR/HER2 inhibitor with IC50 of 0.5/0.4/10/14 nM for wt EGFR/EGFR L858R/EGFR L858R+T790M/HER2 respectively. |
| PC-42499 |
Afatinib
EGFR inhibitor
|
Afatinib (BIBW 2992) is an irreversible, dual EGFR/HER2 inhibitor with IC50 of 0.5/0.4/10/14 nM for wt EGFR/EGFR L858R/EGFR L858R+T790M/HER2 respectively. |
| PC-44668 |
Poziotinib
pan-HER inhibitor
|
Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2/5.3 nM/23.5 nM for HER1/HER2/HER4. |
| PC-42524 |
CL-387785
EGFR inhibitor
|
CL-387785 (EKI785, WAY-EKI785) is a specific, irreversible, covalent EGFR inhibitor with IC50 of 0.37 nM. |
| PC-42522 |
BIBX 1382
EGFR inhibitor
|
BIBX 1382 (Falnidamol) is a selective EGFR inhibitor with IC50 of 3 nM. |
| PC-45895 |
Lapatinib ditosylate
EGFR inhibitor
|
Lapatinib (GW 572016) ditosylate is a reversible, selective dual tyrosine kinase inhibitor of both EGFR and ErbB2 with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. |
| PC-45894 |
Lapatinib
EGFR inhibitor
|
Lapatinib (GW 572016) is a reversible, selective dual tyrosine kinase inhibitor of both EGFR and ErbB2 with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. |
